Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.
Sirius Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in May 2025.
Sirius Therapeutics's investors include OrbiMed, Delos Capital, BioTrack Capital, Hankang Capital, Creacion Ventures.
Sirius Therapeutics is headquartered in San Diego, United States.
Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases.
Sirius Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sirius Therapeutics — Funding & Investors." VCBacked, May 9, 2025, https://www.vcbacked.co/company/sirius-therapeutics. Accessed July 27, 2026.
VCBacked. (2025). Sirius Therapeutics — Funding & Investors. Retrieved July 27, 2026, from https://www.vcbacked.co/company/sirius-therapeutics
{{cite web |title=Sirius Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sirius-therapeutics |website=VCBacked |access-date=July 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated